Filter posts

Fireside Chat with Ken Drazan, MD, Head of Johnson & Johnson Innovation

Day one of the BIO Investor Forum featured a Fireside Chat with Ken Drazan, MD, …

T-Cell Therapies: Best Bets in Pushing Down the Cost Curve and Prioritizing Cancer Targets

New approaches in cancer immunology are achieving promising early-stage results through novel techniques for arming …

Gates Foundation and Grand Challenge Partners Announce New Investments in Breakthrough Science

At an event in Seattle today, the Bill & Melinda Gates Foundation and a group …

New PhRMA report: Nearly 800 Cancer Medicines in Development

A new report from the Pharmaceutical Research and Manufacturers of America (PhRMA) shows that biopharma …

Washington Post: Why Extremely Expensive Drugs Are Often Worth the Cost

Jason Millman highlights a new study published in Health Affairs showing specialty drugs often provide …

Health Affairs: 5 Myths about Cancer Care in America

In the latest issue of Health Affairs, Dana Goldman of the University of Southern California …